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I 
n  this issue,  Saoudi and colleagues expand on their pre- 
vious observation that development of experimental allergic 
encephalitis (EAE) can be suppressed by preimmunizing rats 
with a myelin basic protein (MBP)-derived peptide that has 
been coupled to an anti-IgD antibody (1, 2). Their observa- 
tions illustrate how antigen presentation by a particular cell 
type can induce a form of tolerance, immune deviation, in 
which autoimmune responses are channeled in a harmless direc- 
tion. Types of T  cell tolerance include (a) death of T  cells 
that are specific for a particular MHC-peptide combination 
(clonal deletion); (b) T cell survival in a form that is unrespon- 
sive or hyporesponsive to activating stimuli (anergy); and (c) 
T  cell survival in a form that responds strongly to a partic- 
ular stimulus, but in a way that differs from the standard 
response (immune deviation). Although clonal deletion and 
anergy might seem to be the most complete forms of toler- 
ance, they may be limited by thymic replacement of deleted 
or anergic antigen-specific T cells. Immune deviation, on the 
other hand, can be self-perpetuating because cytokine responses 
of fully differentiated T cells can influence the differentiation 
of newly generated, antigen-stimulated T  cells. 
Immune deviation was first described in the 1960s (3), but 
mechanistic understanding of the process was limited before 
the description of CD4 § T  cell subsets that can be distin- 
guished by the cytokines they produce (4, 5). CD4 + T cells 
can be characterized as Thl cells, which secrete 11:2, lym- 
photoxin (TNF-3), and IFN-3', but not I1:4, IL-5, I1:9, I1:10, 
or II,-13, and Th2 cells that secrete the opposite set of cytokines. 
Cytokine responses that resemble Thl or Th2 responses, but 
are not necessarily made by CD4 + T  cells,  are referred to 
as type 1 or type 2, respectively. Type 1 responses are gener- 
ally associatedwith cytotoxic effects (CTL, activated macro- 
phages that kill ingested microbes, complement-fixing anti- 
body),  while  type  2  responses  are  associated  with  non- 
complement-fixing antibody and allergy-related phenomena 
(eosinophilia, mucosal mastocytosis, IgE) (4-6).  Although 
individual T cells or T cell clones can secrete other combina- 
tions  of cytokines (7),  CD4 +  T  cell responses  in  disease 
states often are predominantly Thl-or Th2-1ike (8,  9). 
CD4 +  T  cells  often  pass  through  a  "Th0"  stage  of 
differentiation in which they secrete both type 1 and type 
2 cytokines (10).  Although cytokine responses can remain 
mixed, the same CD4 § T cells can be induced to secrete ei- 
ther type 1 or type 2 cytokines, depending on the environ- 
ment in which they are activated. Several factors may influence 
T  cell differentiation. 
Cytokine Influences.  IL-12,  IFN-3', IFN-ol, and IFN-3 all 
promote the secretion of IFN-'y and inhibit type 2 cytokine 
secretion (with the exception that IL-12 stimulates 11:10 secre- 
tion) (11-13). IFN-3' itself inhibits type 2 cytokine secretion 
and contributes to the anti-type 2 effect of I1:12. I1:4 stimu- 
lates CD4 + T cells to differentiate into cells that secrete I1:4 
and other type 2 cytokines, and it inhibits type 1 cytokine 
secretion by differentiating CD4 + T cells (14). If II:4 priming 
is essential for the generation of an IL-4 response by most 
naive T cells, I1:4 might initially be produced by basophils 
and/or an NK1 + T  cell subset that expresses this cytokine 
without priming (15,  16). Alternatively, other factors may 
substitute for I1:4 in the stimulation of a Th2 response. Two 
additional cytokines have more complex effects on the im- 
mune system. ILl0 inhibits macrophage antigen presenta- 
tion (17) but has more of an inhibitory effect on Thl responses 
than on Th2 responses, possibly because it suppresses macro- 
phage I1:12 secretion and NK cell IFN-y secretion (18). TGF-3 
suppresses  the development of both Thl- and Th2-related 
effector responses and appears to ultimately promote the de- 
velopment of a type 1 or type 2 response in different situa- 
tions  (19-21). 
Costimulatory Molecules.  Interactions between the B7s on 
APCs and CD28 or CTLA4 on differentiating naive T cells 
are important for induction of both allergy-related responses 
(IgE, eosinophilia)  (22) and for cell-mediated immunity (graft 
rejection) (23). There is no convincing evidence that reagents 
that block such costimulatory interactions modulate a de- 
veloping response in either a type i  or type 2 direction (24). 
Selective B7-1  or B7-2 costimulation predisposes to type 1 
or type 2 cytokine responses, respectively, in some models 
(25), while in other models, either B7-1 or B7-2 costimula- 
tion can induce a type 1 or a type 2 response (reference 26, 
and Gause, W.  C., personal communication). 
Type of  APC.  No independent relationship between type 
of APC and cytokine response has been definitively estab- 
lished. Mice immunized with antigen-pulsed splenic dendritic 
cells or activated B cells were reported to generate both IgG1 
and IgG2a responses, while immunization with antigen-pulsed 
peritoneal macrophages only generated IgG1 responses (27). 
These results suggest that antigen presentation by dendritic 
cells or B cells might be more likely to stimulate IFN-3' produc- 
tion, which enhances IgG2a responses (6),  than would an- 
tigen presentation by peritoneal macrophages. In contrast, 
mice immunized with antibodies that are focused onto B cells 
(anti-IgD), maerophages (anti-CDllb), or dendritic cells (ag- 
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sponses (Finkelman, F., unpublished data), and macrophages, 
dendritic cells, and B cells can all induce either a Thl or a 
Th2 response, given the proper cytokine environment (28). 
Site of Antigen  Presentation.  Inhaled OVA has a greater 
propensity than parenterally injected OVA to stimulate a Th2 
response (29). When administered orally, antigens that stimu- 
late a strong systemic antibody response can induce tolerance 
that is associated with T cell production of TGF-fl (30). These 
results may reflect unique populations of T  cells or APCs 
in the lung or gut,  the influence of cytokines that are ex- 
pressed at these sites,  or other uncharacterized factors. 
Polarized Cytokine Production in Disease States.  Specific 
cytokine patterns are associated with cure or exacerbation of 
both infectious and immune-mediated diseases. Intracellular 
protozoan infections are limited by IFN-3  ~ but exacerbated 
by IL-4, while some gastrointestinal nematode infections are 
controlled by Ib4 and exacerbated by IFN-3~ (8, 9). Atopic 
allergy is mediated by type 2 cytokines (4). In addition, graft 
vs host disease (GVHD) that is characterized by a systemic 
lupus erythematosus-like autoimmune syndrome is associated 
with type 2 cytokine production and is inhibited by anti- 
IL-4 antibody (31). On the other hand, type 1 cytokines are 
produced in acute GVHD,  in which donor CD8 + T  cells 
develop into CTL that destroy the host immune and hema- 
topoietic systems. Treatment with anti-IFN-3  ~ or anti-TNF 
mAb ameliorates disease, and treatment with anti-IL-2 mAb 
converts acute GVHD to autoimmune GVHD (reference 32, 
and Via, C. S., and F. D. Finkelman, manuscript in prepara- 
tion). Thl responses are also critical for the development of 
insulin-dependent diabetes mellitus in nonobese diabetic mice 
and EAE in mice and rats (33). Both disorders can be amelio- 
rated by treating mice with II,-4 before the development of 
clinically apparent disease (34, 35), and the development of 
diabetes  mellitus can be prevented by treating  mice with 
anti-IFN-'y mAb (36). EAE association with type 1 cytokines 
may relate more to the effects of TNF than IFN-% in that 
anti-TNF mAb ameliorates disease, while anti-IFN-3  ~ mAb 
can actually exacerbate disease  (37,  38). 
Association of specific immune-mediated disorders with 
cytokine patterns raises the possibility that immunization with 
a disease-related antigen in a way that would promote the 
development of an opposing set of cytokines might prevent 
disease  development.  Mason  and  colleagues  applied  this 
strategy to prevent the development of EAE by immunizing 
rats with an anti-IgD mAb conjugated to a peptide that is 
a major T cell epitope of MBP (1, 2). Injection of this con- 
jugate both focuses the MBP-derived peptide onto mlgD + 
B cells, which provides a large population of cells capable 
of presenting the antigen to MBP peptide-specific T  cells, 
and it activates  B cells, making them capable of presenting 
antigen in a manner that causes T cell activation rather than 
tolerance (39).  Consistent with a previous study in which 
antigen presentation by anti-IgD antibody-activated B cells 
stimulated a predominantly Th2 response (40), the cytokine 
response made by MBP-spedfic T cells that were primed with 
the anti-IgD mAb-MBP peptide conjugate before challenge 
with MBP in CFA was deviated in the Th2 direction (more 
IL-4, less IFN-3~), as compared to that generated by T  cells 
from unprimed mice injected with MBP in CFA. It remains 
to be established, however, that antigen presentation by B 
cells, as opposed to antigen presentation by any cell type in 
the absence of CFA, is responsible for immune deviation in 
the EAE system. 
Use of Immune Deviation for Treatment of Immune-mediated 
Disorders.  The deviation of established cytokine responses 
is difficult but not impossible. "Desensitization"  to grass pollen 
can be associated with an increase in the IFN-y:IL-4 response 
to the allergen (41); mice immunized once with irradiated 
Schistosoma mansoni cercariae develop a predominantly Thl 
response, while repeated immunization with the same para- 
site causes the response to become predominantly Th2 (42); 
IL-12 treatment starting at the time of inoculation of mice 
with Hetigmosomoides polygyrus causes the secretion of Thl- 
associated cytokines rather than the usual Th2 response; how- 
ever, the response switches to Th2 once the IL-12 treatment 
is discontinued (43). It is not known if any of these phenomena 
involve the actual switching of cytokine production by par- 
tially or fully differentiated T cells or the replacement of one 
T cell population by another. The clinical responses of some 
rheumatoid arthritis and multiple sclerosis patients to orally 
administered type II collagen or MBP, respectively, may rep- 
resent the successful application of immune deviation to human 
diseases (30). It remains to be determined whether immuni- 
zation  with  antigens  targeted to  APCs  may allow  some 
immune-mediated disorders to be treated in a practical and 
effective manner. 
The use of immune deviation as therapy carries potential 
risks as well as benefits. For example, IL-12 treatment of mice 
that would normally develop autoimmune GVHD prevents 
the development of this disorder but causes instead the de- 
velopment of acute GVHD (44).  Further understanding of 
stimuli that induce or suppress  T cell expression of specific 
cytokines and of the roles of specific cytokines in disease patho- 
genesis will facilitate  the use of this double-edged sword in 
the safest manner possible. 
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